Breast Cancer Liquid Biopsy Market Report 2025-2034: Industry Overview, Trends, And Forecast Analysis

We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Is the Current Breast Cancer Liquid Biopsy Market Size and Its Estimated Growth Rate?
Rapid growth has been seen in the breast cancer liquid biopsy market size over the last few years. The market, which is projected to expand from $0.78 billion in 2024 to $0.90 billion in 2025, is estimated to exhibit a compound annual growth rate (CAGR) of 15.0%. Factors such as the progress in next-generation sequencing (ngs), the increasing occurrence of breast cancer, the growing need for non-invasive diagnostic techniques, the surge in acceptance of personalized medicine, and augmented finance for cancer research, are contributing to the historical growth period.

The market size for the breast cancer liquid biopsy is anticipated to experience accelerated growth over the coming years. It is projected to expand to $1.56 billion by 2029, with a compound annual growth rate (CAGR) of 14.7%. This anticipated growth can be linked to factors such as advancements in liquid biopsy assay technology, the increasing use of liquid biopsy in early cancer detection, an upswing in demand for real-time cancer surveillance, wider applications in precise oncology, and increased investment in liquid biopsy R&D. Key market trends to watch include the incorporation of artificial intelligence in liquid biopsy analysis, progress in single-cell sequencing, the development of multi-omics liquid biopsy platforms, enhancements in the sensitivity and specificity of liquid biopsy and the use of digital pcr for ultra-precise mutation identification.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21119

How Are Emerging Segments Shaping the Breast Cancer Liquid Biopsy Market Landscape?
The breast cancer liquid biopsy market covered in this report is segmented -

1) By Product: Consumables, Kits
2) By Biomarkers: Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), Circulating Tumor RNA (ctRNA), Circulating Tumor Cells (CTCs), Cell-free RNA (cfRNA), Other Biomarkers
3) By Application: Early Detection Or Screening, Diagnosis, Other Applications
4) By End Users: Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories

Subsegments:
1) By Consumables: Reagents, Polymerase Chain Reaction (PCR) Assays, Sequencing Panels, Sample Collection Tubes
2) By Kits: DNA-based Liquid Biopsy Kits, RNA-based Liquid Biopsy Kits, Multi-marker Liquid Biopsy Kits

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21119&type=smp

Which Growth Factors Are Influencing Breast Cancer Liquid Biopsy Market Expansion?
The surge in breast cancer instances is anticipated to fuel the expansion of the breast cancer liquid biopsy market. Breast cancer is a form of cancer that originates in the breast cells, particularly in the lobules (where milk is produced) or ducts (which transport milk to the nipple). The uptick in breast cancer incidents can be attributed to factors such as genetic factors, hormone imbalances, an aging population, lifestyle modifications, obesity, alcohol intake, a lack of physical exercise, radiation exposure, and environmental pollutants. A liquid biopsy for breast cancer aids in the treatment process by identifying circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in the bloodstream, which provides a real-time disease monitoring. It aids in evaluating treatment response, discovering therapy resistance, and pinpointing genetic mutations for customised therapy. For example, the American Cancer Society, a nonprofit organization based in the US focusing on cancer research, education, advocacy, and patient support, suggests that the volume of new breast cancer cases will escalate to 319,750 in 2025, a rise from 313,510 cases in 2024. Consequently, the surge in breast cancer instances is contributing to the expansion of the breast cancer liquid biopsy market.

Who Are the Dominant Players Across Different Breast Cancer Liquid Biopsy Market Segments?
Major companies operating in the breast cancer liquid biopsy market are Johnson & Johnson Private Limited, Roche Diagnostics, Merck KGaA, Thermo Fisher Scientific, Siemens Healthineers, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Qiagen N.V., Myriad Genetics Inc., NeoGenomics Laboratories, Guardant Health Inc., Twist Bioscience, Foundation Medicine Inc., Biodesix Inc., Menarini Silicon Biosystems, Datar Cancer Genetics, Abcam plc, OncoDNA SA, Genomic Health Inc., RainDance Technologies, Biocept Inc., Fluxion Biosciences Inc., Angle plc

What Trends Are Driving Growth in The Breast Cancer Liquid Biopsy Market?
Leading firms in the breast cancer liquid biopsy market are concentrating on crafting novel products such as companion diagnostics. These products allow for personalized treatment plans by identifying individuals who will benefit from certain therapies. Companion diagnostics use liquid biopsy technologies to identify various biomarkers including genetic mutations, circulating tumor DNA (ctDNA), or protein expressions that show responsiveness to treatment. For example, in January 2023, Guardant Health Inc., a biotechnology company based in the U.S., was given approval by the Food and Drug Administration (FDA) for its Guardant360 CDx liquid biopsy test. This test is a companion diagnostic for Menarini Group's ORSERDU (elacestrant), a medication for advanced or metastatic breast cancer patients with ESR1 mutations. The approval permits oncologists to utilize this test for extensive genomic profiling and to identify patients who could gain from the specific therapy. This is Guardant Health's inaugural FDA approval in breast cancer, broadening its influence in precision oncology.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/breast-cancer-liquid-biopsy-global-market-report

Which Geographic Regions Are Expected to Dominate the Breast Cancer Liquid Biopsy Market in the Coming Years?
North America was the largest region in the breast cancer liquid biopsy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer liquid biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Breast Cancer Liquid Biopsy Market?
2. What is the CAGR expected in the Breast Cancer Liquid Biopsy Market?
3. What Are the Key Innovations Transforming the Breast Cancer Liquid Biopsy Industry?
4. Which Region Is Leading the Breast Cancer Liquid Biopsy Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.